Immunogen | IMGN - Des Atouts



Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Astellas Pharma JPY 3.69T 125.48B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Exelixis USD 2.49B 99.36M 2026-06
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Heron Therapeutics USD 252.26M 6.05M 2026-06
Intrexon USD 73.16M 77.88M 2024-06
Karyopharm Therapeutics USD 131.42M 23M 2026-03
MacroGenics USD 345.41M 127.54M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 201.13B 6.49B 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 128.02B 1.22B 2026-03